(NVCR) Novocure - Ratings and Ratios
TTFields, Optune Gio, Optune Lua, Clinical Trials
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 69.8% |
| Value at Risk 5%th | 92.1% |
| Relative Tail Risk | -19.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.25 |
| Alpha | -76.68 |
| CAGR/Max DD | -0.58 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.464 |
| Beta | 1.242 |
| Beta Downside | 0.907 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.83% |
| Mean DD | 77.59% |
| Median DD | 85.19% |
Description: NVCR Novocure November 14, 2025
Novocure Ltd (NASDAQ:NVCR) is a Swiss-based oncology firm that develops, manufactures, and commercializes Tumor Treating Fields (TTFields) medical-device platforms-principally Optune Gio and Optune Lua-for solid-tumor cancers across the United States, Europe, Japan, Greater China, and other international markets. The company’s pipeline extends TTFields therapy into brain metastases, gastric, glioblastoma, liver, non-small cell lung, pancreatic, and ovarian cancers through ongoing clinical trials.
As of the most recent quarter (Q2 2024), Novocure reported ≈ $140 million in revenue, a 12% year-over-year increase driven by expanding Optune Gio adoption in the U.S. and the launch of Optune Lua in Europe. The firm’s gross margin stabilized around 78%, reflecting the high-value, low-variable-cost nature of its device business. Key economic drivers include rising oncology drug-device combo reimbursement rates in the U.S. Medicare system and the broader secular growth of the global oncology market, which the IDC forecasts to exceed $300 billion by 2028. A material risk remains the reliance on a single FDA-cleared technology platform; any adverse safety signal could materially impact cash flow.
For readers interested in a deeper, data-centric assessment of Novocure’s valuation dynamics, a quick look at ValueRay’s analyst toolkit can surface comparable peer multiples and scenario-based cash-flow models that may sharpen your investment thesis.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-177.7m TTM) > 0 and > 6% of Revenue (6% = 38.5m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 1.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 65.99% (prev 62.36%; Δ 3.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.03 (>3.0%) and CFO -34.5m > Net Income -177.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (111.9m) change vs 12m ago 3.38% (target <= -2.0% for YES) |
| Gross Margin 75.37% (prev 76.41%; Δ -1.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.73% (prev 47.28%; Δ 2.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.38 (EBITDA TTM -107.5m / Interest Expense TTM 11.7m) >= 6 (WARN >= 3) |
Altman Z'' -2.93
| (A) 0.31 = (Total Current Assets 1.20b - Total Current Liabilities 776.0m) / Total Assets 1.36b |
| (B) -0.93 = Retained Earnings (Balance) -1.27b / Total Assets 1.36b |
| (C) -0.09 = EBIT TTM -121.0m / Avg Total Assets 1.29b |
| (D) -1.25 = Book Value of Equity -1.27b / Total Liabilities 1.02b |
| Total Rating: -2.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.15
| 1. Piotroski 1.0pt |
| 2. FCF Yield -5.25% |
| 3. FCF Margin -10.15% |
| 4. Debt/Equity 2.34 |
| 5. Debt/Ebitda -4.22 |
| 6. ROIC - WACC (= -22.04)% |
| 7. RoE -50.29% |
| 8. Rev. Trend 76.52% |
| 9. EPS Trend -38.28% |
What is the price of NVCR shares?
Over the past week, the price has changed by -3.79%, over one month by +10.70%, over three months by +0.08% and over the past year by -56.61%.
Is NVCR a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NVCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.8 | 91.7% |
| Analysts Target Price | 24.8 | 91.7% |
| ValueRay Target Price | 8 | -38.4% |
NVCR Fundamental Data Overview January 01, 2026
P/E Forward = 909.0909
P/S = 2.305
P/B = 4.3535
P/EG = -0.47
Beta = 0.823
Revenue TTM = 642.3m USD
EBIT TTM = -121.0m USD
EBITDA TTM = -107.5m USD
Long Term Debt = 194.6m USD (from longTermDebt, last quarter)
Short Term Debt = 560.6m USD (from shortTermDebt, last quarter)
Debt = 797.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 453.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.24b USD (1.48b + Debt 797.9m - CCE 1.04b)
Interest Coverage Ratio = -10.38 (Ebit TTM -121.0m / Interest Expense TTM 11.7m)
FCF Yield = -5.25% (FCF TTM -65.2m / Enterprise Value 1.24b)
FCF Margin = -10.15% (FCF TTM -65.2m / Revenue TTM 642.3m)
Net Margin = -27.66% (Net Income TTM -177.7m / Revenue TTM 642.3m)
Gross Margin = 75.37% ((Revenue TTM 642.3m - Cost of Revenue TTM 158.2m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 73.88%)
Tobins Q-Ratio = 0.91 (Enterprise Value 1.24b / Total Assets 1.36b)
Interest Expense / Debt = 1.46% (Interest Expense 11.7m / Debt 797.9m)
Taxrate = -24.14% (negative due to tax credits) (7.25m / -30.0m)
NOPAT = -150.3m (EBIT -121.0m * (1 - -24.14%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.55 (Total Current Assets 1.20b / Total Current Liabilities 776.0m)
Debt / Equity = 2.34 (Debt 797.9m / totalStockholderEquity, last quarter 341.3m)
Debt / EBITDA = -4.22 (negative EBITDA) (Net Debt 453.3m / EBITDA -107.5m)
Debt / FCF = -6.96 (negative FCF - burning cash) (Net Debt 453.3m / FCF TTM -65.2m)
Total Stockholder Equity = 353.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.05% (Net Income -177.7m / Total Assets 1.36b)
RoE = -50.29% (Net Income TTM -177.7m / Total Stockholder Equity 353.2m)
RoCE = -22.09% (EBIT -121.0m / Capital Employed (Equity 353.2m + L.T.Debt 194.6m))
RoIC = -14.53% (negative operating profit) (NOPAT -150.3m / Invested Capital 1.03b)
WACC = 7.52% (E(1.48b)/V(2.28b) * Re(10.59%) + D(797.9m)/V(2.28b) * Rd(1.46%) * (1-Tc(-0.24)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.28%
Fair Price DCF = unknown (Cash Flow -65.2m)
EPS Correlation: -38.28 | EPS CAGR: -5.86% | SUE: 0.80 | # QB: 0
Revenue Correlation: 76.52 | Revenue CAGR: 6.25% | SUE: 1.51 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.37 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.48 | Chg30d=+0.010 | Revisions Net=+3 | Growth EPS=-7.2% | Growth Revenue=+5.6%
Additional Sources for NVCR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle